Development of human iPSC-derived hepatocytes for drug discovery, translational research and toxicity testing

Traditional liver models face challenges including primary cell scarcity, poor physiological relevance in immortalized lines and high variability in conventional hiPSC methods. These limitations hinder drug-induced liver injury (DILI) prediction, contributing to high clinical attrition.

To address this, learn in this scientific poster how ioHepatocytes were generated using opti-ox™ deterministic programming and how they demonstrate robust Phase I-III metabolism via functional CYP3A, CYP2B6, and CYP1A2 enzymes. Validated against known hepatotoxins, uncover how ioHepatocytes show dose-dependent toxicity correlating with clinical DILI severity and mimic PHH responses with superior consistency, to provide a scalable, high-predictivity platform for drug discovery.